Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/heartjnl-2020-317056 http://scihub22266oqcxt.onion/10.1136/heartjnl-2020-317056 32354800!7211105!32354800     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Heart 2020 ; 106 (15): 1132-1141 Nephropedia Template TP {{tp|p=32354800|t=2020. Cardiovascular manifestations and treatment considerations in COVID-19 |pdf=|usr=}}{{32354800}} gab.com Text Cardiovascular manifestations and treatment considerations in COVID-19 JO: Heart http://www.kidney.de/pget.php?&tw=1&pmid=32354800 #FOAvip Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support. Twit Text FOAVip Cardiovascular manifestations and treatment considerations in COVID-19 ????Heart http://www.kidney.de/pget.php?&tw=1&pmid=32354800 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32354800 #FOAvip English Wikipedia <ref>{{Cite pmid|32354800}}</ref> Cardiovascular manifestations and treatment considerations in COVID-19 #MMPMID32354800 Kang Y; Chen T; Mui D; Ferrari V; Jagasia D; Scherrer-Crosbie M; Chen Y; Han Y Heart 2020[Aug]; 106 (15): 1132-1141 PMID32354800show ga Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support. |Angiotensin Receptor Antagonists/therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH] |Anticoagulants/therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |Betacoronavirus[MESH] |Biomarkers/blood[MESH] |COVID-19[MESH] |Cardiovascular Diseases/*epidemiology/therapy[MESH] |Chloroquine/therapeutic use[MESH] |Comorbidity[MESH] |Coronavirus Infections/*epidemiology/mortality[MESH] |Cytokine Release Syndrome/epidemiology[MESH] |Disseminated Intravascular Coagulation/epidemiology[MESH] |Extracorporeal Membrane Oxygenation[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Influenza, Human/mortality[MESH] |Lung/metabolism/pathology[MESH] |Myocardium/metabolism/pathology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Pneumonia, Viral/*epidemiology[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/mortality[MESH] |Troponin/blood[MESH]Cardiovascular manifestations and treatment considerations in COVID-19(epmc).pdf DeepDyve Pubget Overpricing